LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area

被引：0

作者：

Liming Zhao ^{[1
]}

Jiamei Liu ^{[1
]}

Yin Liu ^{[1
]}

Zhenna Huang ^{[2
]}

Xuxiao Ye ^{[2
]}

Jeff L. Lange ^{[3
]}

Nafeesa Dhalwani ^{[3
]}

Fan Yang ^{[1
]}

Zizhao Zhang ^{[4
]}

Kangyin Chen ^{[4
]}

Hao Zhang ^{[4
]}

Jifang Zhou ^{[1
]}

机构：

[1] School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, Nanjing

[2] Center for Observational Research, Amgen China, Shanghai

[3] Center for Observational Research, Amgen Inc., Thousand Oaks

[4] Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin

来源：

Advances in Therapy | 2025年 / 42卷 / 6期

关键词：

Evolocumab; LDL-C; Lipid-lowering therapy; Real-world evidence; Tianjin Regional Healthcare Database;

D O I：

10.1007/s12325-025-03199-3

中图分类号：

学科分类号：

摘要：

Introduction: Clinical trials have shown that adding evolocumab to statin therapy reduces low-density lipoprotein cholesterol (LDL-C) levels by approximately 60%. Given differences in patient characteristics and standards of care between trial and real-world settings, we conducted a cohort study to evaluate the LDL-C reduction achieved with evolocumab in clinical practice of China. Methods: The data source was the Tianjin Regional Healthcare Database (TRHD), which includes linked electronic health records (EHR) of public hospitals serving over 15 million residents in the Tianjin metropolitan area. The study cohort included adult patients with atherosclerotic cardiovascular disease (ASCVD) who added evolocumab to their statin therapy between 2019 and 2023. Key inclusion criteria were use of the same statin intensity before and after evolocumab initiation and available LDL-C values at baseline (within 90 days before initiation) and follow-up (15–90 days after initiation). Descriptive statistics were used to analyze LDL-C change between baseline and follow-up. To provide the context for evolocumab use and for study method assessment, we included another cohort of patients with stable statin intensity (unchanged for at least 180 days)—a cohort with minimal clinical expectation of further LDL-C change over time. Results: At baseline, the median (interquartile range [IQR]) LDL-C level was 3.44 (2.73–4.15) mmol/L in the evolocumab cohort (n = 395) and 2.20 (1.72–2.92) mmol/L in the stable statin cohort (n = 4160). At follow-up, the mean (95% confidence interval [CI]) percentage reduction in LDL-C levels was 63.0% (60.5–65.5%) in the evolocumab cohort and 2.5% (0.3–4.7%) in the stable statin cohort. Conclusions: LDL-C reductions in patients who added evolocumab to statin therapy in real-world clinical practice in China align with reductions observed in clinical trials. © The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2025.

引用

页码：2874 / 2887

页数：13

共 37 条

[1] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019, Lancet, pp. 1204-1222, (2020)
[2] Li J.J., Zhao S.P., Zhao D., Et al., 2023 Chinese guideline for lipid management, Front Pharmacol, 14, (2023)
[3] Zhou M., Wang H., Zeng X., Et al., Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 394, pp. 1145-1158, (2019)
[4] Wang Z., Ma L., Liu M., Fan J., Hu S., Writing Committee of the Report on Cardiovascular Health and Diseases in China. Summary of the 2022 Report on Cardiovascular Health and Diseases in China, Chin Med J (Engl), 136, 24, pp. 2899-2908, (2023)
[5] Sun P., Zhao L., Zhang N., Et al., Bioactivity of dietary polyphenols: the role in LDL-C lowering, Foods, 10, 11, (2021)
[6] Wilkinson M.J., Lepor N.E., Michos E.D., Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum, J Am Heart Assoc, 12, 11, (2023)
[7] Tokgozoglu L., Libby P., The dawn of a new era of targeted lipid-lowering therapies, Eur Heart J, 43, 34, pp. 3198-3208, (2022)
[8] Lamb Y.N., Inclisiran: first approval, Drugs, 81, 3, pp. 389-395, (2021)
[9] Grundy S.M., Stone N.J., Bailey A.L., Et al., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 139, 25, pp. e1082-e1143, (2019)
[10] Masana L., Ibarretxe D., Plana N., Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy, Curr Cardiol Rep, 22, 8, (2020)

← 1 2 3 4 →